Suzhou Bojin Biotechnology
Specializing in the development of tumor immunotherapy drugs
About Suzhou Bojin Biotechnology
Guangzhou Boji Medical and Biotechnology Co., Ltd., also known as Boji Biomedicals (stock code: 300404), is a high-tech contract research organization (CRO) and contract development and manufacturing organization (CDMO). Founded in 2002 and listed on the Shenzhen GEM in 2015, the company provides comprehensive, one-stop services for domestic and international pharmaceutical enterprises.
The company's services cover all stages of new drug research and development. This includes project approval, activity screening, pharmaceutical research on active pharmaceutical ingredients (APIs) and preparations, and drug evaluation for pharmacodynamics and toxicology. Boji also handles clinical research, registration services (including Sino-American), and the commercialization of technological achievements for drugs, medical devices, and health products.
Headquartered in Guangzhou, Boji has established a significant presence with 9 wholly-owned subsidiaries and over 10 holding companies. Its workforce consists of nearly 800 biomedical R&D professionals and legislative experts. The company has demonstrated international service capabilities, undertaking multi-center clinical trials for multinational pharmaceutical firms. Dr. Wang Tingchun, a Medical Doctor from Jinan University, is a key figure with over 20 years of clinical and CRO management experience, leading numerous major national and provincial science and technology projects.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.0/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Oct 2023 | $14M | $55M | Changda Investment · Gedian Construction Investment | ↗ |
Growth signals
Latest recorded traffic for Suzhou Bojin Biotechnology is 640 monthly website visits, up 814.3% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Bojin Biotechnology in its local ecosystem
The Suzhou Bojin Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- CIChangda Investment
- GIGedian Construction Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Bojin Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Bojin Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.